Gentler chemo combo tested in High-Risk leukemia fight

This study is testing whether adding a drug called venetoclax to a lower-intensity chemotherapy regimen improves outcomes for people newly diagnosed with a high-risk type of leukemia (Ph+ ALL). All participants will receive a targeted pill (olverembatinib) continuously and may also receive an immunotherapy drug (blinatumomab). The main goals are to see if this combination leads to a very low level of leukemia cells early on and improves survival without the disease returning.